Results 251 to 260 of about 137,192 (357)

Trichostatin A Sensitizes Tumor Cells to Apoptosis Induced by Soluble Trimeric TRAIL‐Expressing Human Mesenchymal Stromal Cells

Cancer Science, EarlyView.
Human mesenchymal stromal cells (MSCs) were engineered to secrete an isoleucine‐zippered soluble trimeric TRAIL (SCZT) and evaluated with trichostatin A (TSA) to overcome TRAIL resistance. TSA upregulated DR5 and amplified caspase‐8–dependent apoptosis in vitro; in vivo, tumor‐homing MSCs combined with TSA suppressed the growth of both TRAIL‐sensitive ...
Ryosuke Uchibori, Ken Ohmine, Keiya Ozawa   +2 more
wiley   +1 more source

Safety, pharmacokinetics, and efficacy of abexinostat, an novel histone deacetylase inhibitor, in Chinese patients with relapsed/refractory B cell non-Hodgkin lymphoma: a Phase 1 study. [PDF]

BMC Cancer
Gui L, Xie Z, Qin Y, Liu P, Yang J, Chen X, Li Z, Tao R, Shi Y.   +8 more
europepmc   +1 more source

Endocrine Resistance Score Based on Three Key Genes Predicts Prognosis and Reveals Potential Therapeutic Targets for ER+HER2− Breast Cancer

Cell Proliferation, EarlyView.
We generated endocrine‐resistant BC cell lines and identified CLEC3A, PCDH10, and ST3GAL1 as key endocrine‐resistant genes. More importantly, we validated their role in mediating resistance through PI3K‐AKT signalling and developed a predictive ERS with strong clinical relevance.
Liqin Ping, Lewei Zhu, Nian Chen, Xikun Liu, Jirui Zhong, Xiaoqing Sun, Hailin Tang, Kaiming Zhang   +7 more
wiley   +1 more source

The Impact of the Histone Deacetylase Inhibitor-Sodium Butyrate on Complement-Mediated Synapse Loss in a Rat Model of Neonatal Hypoxia-Ischemia. [PDF]

Mol Neurobiol
Ziabska K, Gewartowska M, Frontczak-Baniewicz M, Sypecka J, Ziemka-Nalecz M.   +4 more
europepmc   +1 more source

Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells [PDF]

, 2015
Ahrum Min, Seock‐Ah Im, Debora Keunyoung Kim, Sang-Hyun Song, Hee Jun Kim, Kyung-Hun Lee, Tae‐Yong Kim, Sae‐Won Han, Do‐Youn Oh, Tae‐You Kim, Mark J. O’Connor, Yung‐Jue Bang   +11 more
openalex   +1 more source

Liquid–Liquid Phase Separation in Major Hallmarks of Cancer

Cell Proliferation, EarlyView.
Aberrant condensates formed through phase separation are involved in the dysregulation of various critical cellular processes, including genome stability, transcriptional regulation and signal transduction, thereby promoting malignant transformation and the acquisition of multiple cancer hallmarks.
Chen‐chen Xie, Ting Wang, Xin‐ran Liu, Yan Wang, Qin Dang, Tian Ding, Jia‐qi Xu, Xian‐jun Yu, Hai Lin, Xiao‐wu Xu, Yi Qin   +10 more
wiley   +1 more source

Preconditioning of Human Umbilical Cord Mesenchymal Stem Cells with a Histone Deacetylase Inhibitor: Valproic Acid. [PDF]

Balkan Med J
Işıldar B, Özkan S, Koyutürk M.
europepmc   +1 more source

Pulmonary Vascular Endothelial Cells in Lung Diseases: Mechanisms, Therapeutic Strategies, and Future Directions

Cell Proliferation, EarlyView.
The pathogenic mechanisms of pulmonary vascular endothelial cells (VECs) in lung diseases and their multimodal therapeutic strategies. ABSTRACT Pulmonary vascular endothelial cells (VECs) are essential for the normal function of the lung, through maintaining vascular barrier integrity, regulating blood flow, and participating in inflammatory responses ...
Qianyue Liu, Hongshuai Zheng, Jing Liu, Ming Gao, Faquan Lin, Lin Liao   +5 more
wiley   +1 more source

Identification of a histone deacetylase inhibitor as a therapeutic candidate for congenital central hypoventilation syndrome. [PDF]

Mol Ther Nucleic Acids
Africano C, Bachetti T, Uva P, Pitollat G, Del Zotto G, Giacopelli F, Recchi G, Lenfant N, Madani A, Beckouche N, Thoby-Brisson M, Ceccherini I.   +11 more
europepmc   +1 more source

Beyond PD‐1: Mechanisms of Resistance to Checkpoint Blockade in Classical Hodgkin Lymphoma and Next‐Generation Immune Strategies

European Journal of Haematology, EarlyView.
ABSTRACT PD‐1 inhibitors have reshaped the treatment landscape of classical Hodgkin lymphoma, yet a substantial proportion of patients exhibit primary or acquired resistance driven by tumor‐intrinsic alterations, immunosuppressive microenvironmental signals, metabolic constraints, and EBV‐mediated modulation.
Santino Caserta, Enrica Antonia Martino, Mamdouh Skafi, Maria Eugenia Alvaro, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source